Contact Us
Drug Search Results
More Filters [+]

ALLO-213

Alternative Names: ALLO-213, ALLO213, ALLO 213
Latest Update: 2023-01-25
Latest Update Note: News Article

Product Description

Mechanisms of Action: CAR-T,DLL3

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Allogene Therapeutics
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: David Chang
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ALLO-213

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

01/25/2023

News Article

 Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions